Document Detail

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
MedLine Citation:
PMID:  18278193     Owner:  NLM     Status:  MEDLINE    
Variability in response to antiplatelet agents has prompted the development of point-of-care (POC) technology. In this study, we compared the VerifyNow P2Y12 (VN-P2Y12) POC device with light transmission aggregometry (LTA) in subjects switched directly from clopidogrel to prasugrel. Healthy subjects on aspirin were administered a clopidogrel 600 mg loading dose (LD) followed by a 75 mg/d maintenance dose (MD) for 10 days. Subjects were then switched to a prasugrel 60 mg LD and then 10 mg/d MD for 10 days (n = 16), or to a prasugrel 10 mg/d MD for 11 days (n = 19). Platelet function was measured by LTA and VN-P2Y12 at baseline and after dosing. Clopidogrel 600 mg LD/75 mg MD treatment led to a reduction in P2Y(12) reaction units (PRU) from baseline. A switch from clopidogrel MD to prasugrel 60 mg LD/10 mg MD produced an immediate decrease in PRU, while a switch to prasugrel 10 mg MD resulted in a more gradual decline. Consistent with the reduction in PRU, device-reported percent inhibition increased during both clopidogrel and prasugrel regimens. Inhibition of platelet aggregation as measured by LTA showed a very similar pattern to that found with VN-P2Y12 measurement, irrespective of treatment regimens. The dynamic range of VN-P2Y12 appeared to be narrower than that of LTA. With two different thienopyridines, the VN-P2Y12 device, within a somewhat more limited range, reflected the overall magnitude of change in aggregation response determined by LTA. The determination of the clinical utility of such POC devices will require their use in clinical outcome studies.
Joseph A Jakubowski; Christopher D Payne; Ying G Li; John T Brandt; David S Small; Nagy A Farid; Daniel E Salazar; Kenneth J Winters
Related Documents :
18278193 - The use of the verifynow p2y12 point-of-care device to monitor platelet function across...
1004943 - Studies on the modification of renal lesions due to aspirin and oxyphenbutazone in the ...
11346183 - Effect of osaterone acetate administration on prostatic regression rate, peripheral blo...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  99     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-18     Completed Date:  2008-04-22     Revised Date:  2008-07-08    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  409-15     Citation Subset:  IM    
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / administration & dosage
Blood Coagulation Tests / instrumentation*,  methods
Blood Platelets / drug effects*,  metabolism
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Monitoring / instrumentation*,  methods
Middle Aged
Piperazines / administration & dosage*
Platelet Aggregation / drug effects*
Platelet Aggregation Inhibitors / administration & dosage*
Point-of-Care Systems*
Receptors, Purinergic P2 / antagonists & inhibitors*,  blood
Reference Values
Reproducibility of Results
Thiophenes / administration & dosage*
Ticlopidine / administration & dosage,  analogs & derivatives*
Reg. No./Substance:
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Receptors, Purinergic P2; 0/Thiophenes; 0/prasugrel; 0/purinoceptor P2Y12; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII.
Next Document:  Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient...